OmniAb Business Combination Approved by APAC Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright
October 25, 2022 10:47 AM EDTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Ligand Pharma (NASDAQ: LGND) to $135.00 (from $310.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced that the combination between OmniAb and Avista Public Acquisition Corp. II (AHPA; not rated) was... More
